CD79A and COVID-19: Based on the published protocol for RBD construction [9], we developed an ELISA to detect IgM, IgA and IgG antibodies against COVID-19 and tested its performance in the Israeli population with hundreds of samples obtained from COVID-19 patients and non-COVID-19 individuals.